Does treatment sequence affect outcomes in patients with metaplastic breast cancer?

• Published in: The American journal of surgery 2021-04, Vol.221 (4), p.701-705
• Main Authors: Ladipo, Oluwatomi L., Ren, Yi, Caddell, Keenan B., Sampathkumar, Anuyuga, Almond, Chandra A., Fayanju, Oluwadamilola M.
• Format: Article
• Language: English
• Subjects: Adjuvant; Adult; Age; Age Factors; Aged; Breast cancer; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cancer therapies; Chemotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Hispanic people; Histology; Humans; Kaplan-Meier Estimate; Medical prognosis; Metaplastic; Middle Aged; Mutation; Neoadjuvant; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Patients; Prognosis; Radiation; Radiotherapy, Adjuvant; Rank tests; Survival; Treatment sequence
• ISSN: 0002-9610; 1879-1883
• DOI: 10.1016/j.amjsurg.2021.01.007

We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p